Verve Therapeutics, Inc. (VERV)
|Net Income (ttm)||n/a|
|Day's Range||44.14 - 45.80|
|52-Week Range||29.50 - 78.00|
|Est. Earnings Date||Nov 11, 2021|
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. The current paradigm of chronic care is fragile – requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access – and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editi... [Read more...]
Financial PerformanceFinancial Statements
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today...
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, toda...
Verve Therapeutics' Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular Disease
Verve Therapeutics Inc (NASDAQ: VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101. VERVE-101 is a potential single-course gene-editing treatmen...
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021
The dictionary describes the word “verve” as having energy, or vitality. It seems appropriate, then, that shares of biotech startup Verve Therapeutics, Inc. ( VERV , Financial) are up nearly $170% to $5...
Find out why these stocks are climbing higher.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pr...
Verve Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
A team of researchers from Verve Therapeutics and the Perelman School of Medicine at the University of Pennsylvania has developed a CRISPR gene-editing technique that lowered the levels of cholesterol i...
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Bl...
VerveTx Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates